Loading...
Loading...
NVAX| Name | Value |
|---|---|
| Revenues | 84.5M |
| Cost of Revenue | 60.6M |
| Gross Profit | 23.9M |
| Operating Expense | 157.9M |
| Operating I/L | -134.0M |
| Other Income/Expense | 11.7M |
| Interest Income | 0.0M |
| Pretax | -122.3M |
| Income Tax Expense | -1.0M |
| Net Income/Loss | -121.3M |
Novavax, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of vaccines for infectious diseases. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine in Phase III trials, NanoFlu, a seasonal quadrivalent influenza vaccine in Phase 3 clinical trial, and ResVax, a respiratory syncytial virus (RSV) vaccine candidate. Novavax also has collaboration with Takeda Pharmaceutical for the development and commercialization of NVX-CoV2373. The company generates revenue through the development, manufacturing, and commercialization of its vaccine candidates.
